Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (430)	3/5/2003 12:45:35 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 897

>> I'll sniff around more and see if i'll find a better short opportunity. << Ralf: I saw your post to the "valuation" thread...... >> However i have a hard time getting enthusiastic about the sector any more, with the funding essentially closed, even those quite well funded companies will hang out dry in 2-3 years. << Apart from those that you focus on (KOSN, TLRK, etc.), have you considered shorting VPHM? As we know, (1) i.p., preclinical work and early clinical studies have no value, and (2) there will never be another drug (medicine) developed anywhere, much less at VPHM. After a few more quarters (the buy-back allocation was almost exhausted as of 12/31), their book will turn negative. So it's only a matter of time? Of course, you'd need to have a broker that would allow you to short a low-priced stock. Rick